FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2016090125> ?p ?o ?g. }

• W2016090125 abstract "Background: Dysregulation of the PI3K signaling pathway, either through activating mutations, amplification of PI3K or deletion of PTEN has been linked to a wide range of hyperproliferative diseases. The development of small molecule modulators of key proteins in this signaling cascade has focused mainly on mTOR or PI3K. Recent investigations have shown a significant overlap in the activity of small molecule inhibitors against these two proteins. Inhibitors that are currently progressing through preclinical and early clinical development have been shown to affect both mTOR and PI3K to some extent. However, most reported inhibitors do not inhibit both of these kinases in a close dose range. Our drug discovery program has focused on equipotent inhibition of both targets. SB2312 is a novel compound with very favorable drug‐like properties, giving rise to equivalent targeting of both mTOR and PI3K in cells and tumor tissue and resulting in a more efficient inhibition of this pathway compared to reference compounds currently under evaluation in clinical trials. Methods:In vitro‐IC50 for mTOR and PI3K were determined using recombinant enzymes. Inhibitory activity of SB2312 on the mTOR/PI3K signaling pathway was determined by Western‐blot analysis, Surefire assays, and proliferation assays in various cancer cell lines. Efficacious doses of SB2312 or reference compounds were selected after pharmacokinetic and biomarker analysis of PC3 tumor‐bearing mice, treated with single oral doses. Anti‐tumor efficacy of SB2312 and reference compounds was evaluated in mouse xenograft models after continuous daily oral dosing. Results: SB2312 is a potent and selective dual mTOR and PI3K inhibitor (IC50: 55 nM and 18 nM, respectively) and has no significant activity on a large panel of protein kinases or enzymes and receptors. Efficient and equivalent inhibition of mTOR and PI3K in human cell lines was demonstrated by blockade of the phosphorylation of S6KT389 (IC50= 70 nM) and AKTS473 (IC50= 21 nM). SB2312 inhibits the proliferation of a broad range of human tumor cell lines independently of their PI3K pathway mutation status (IC50= 112–882 nM) and is also effective against rapamycin‐resistant cell lines. SB2312 has very favorable physicochemical and pharmacokinetic properties, with high oral bioavailability and tumor exposure. Efficient and sustained inhibition of PI3K and mTOR was demonstrated in tumor tissues from a PC3 tumor xenograft model, along with dose‐dependent anti‐tumor activity at very well tolerated doses. Tumor growth inhibition was 53%, 105%, and 117% at 11, 33, and 80 mg/kg SB2312, respectively, without any body weight loss at any of these doses. Summary: Herein, we report SB2312, a novel, potent and selective dual mTOR/PI3K inhibitor with excellent drug‐like properties. Our studies show superior and sustained blockade of the mTOR/PI3K pathway and high antitumor efficacy at well tolerated doses. Citation Information: Mol Cancer Ther 2009;8(12 Suppl):B138." @default.
• W2016090125 created "2016-06-24" @default.
• W2016090125 creator A5011210921 @default.
• W2016090125 creator A5016939059 @default.
• W2016090125 creator A5028109963 @default.
• W2016090125 creator A5053039165 @default.
• W2016090125 creator A5058833052 @default.
• W2016090125 creator A5066743008 @default.
• W2016090125 creator A5068121579 @default.
• W2016090125 creator A5073678842 @default.
• W2016090125 creator A5076145300 @default.
• W2016090125 creator A5077590208 @default.
• W2016090125 creator A5081388884 @default.
• W2016090125 creator A5089942407 @default.
• W2016090125 date "2009-12-10" @default.
• W2016090125 modified "2023-09-26" @default.
• W2016090125 title "Abstract B138: SB2312, a novel and potent dual inhibitor of mTOR and PI3K with high target inhibition and antitumor efficacy" @default.
• W2016090125 doi "https://doi.org/10.1158/1535-7163.targ-09-b138" @default.
• W2016090125 hasPublicationYear "2009" @default.
• W2016090125 type Work @default.
• W2016090125 sameAs 2016090125 @default.
• W2016090125 citedByCount "0" @default.
• W2016090125 crossrefType "proceedings-article" @default.
• W2016090125 hasAuthorship W2016090125A5011210921 @default.
• W2016090125 hasAuthorship W2016090125A5016939059 @default.
• W2016090125 hasAuthorship W2016090125A5028109963 @default.
• W2016090125 hasAuthorship W2016090125A5053039165 @default.
• W2016090125 hasAuthorship W2016090125A5058833052 @default.
• W2016090125 hasAuthorship W2016090125A5066743008 @default.
• W2016090125 hasAuthorship W2016090125A5068121579 @default.
• W2016090125 hasAuthorship W2016090125A5073678842 @default.
• W2016090125 hasAuthorship W2016090125A5076145300 @default.
• W2016090125 hasAuthorship W2016090125A5077590208 @default.
• W2016090125 hasAuthorship W2016090125A5081388884 @default.
• W2016090125 hasAuthorship W2016090125A5089942407 @default.
• W2016090125 hasConcept C161624437 @default.
• W2016090125 hasConcept C184235292 @default.
• W2016090125 hasConcept C185592680 @default.
• W2016090125 hasConcept C2777609662 @default.
• W2016090125 hasConcept C502942594 @default.
• W2016090125 hasConcept C55493867 @default.
• W2016090125 hasConcept C62478195 @default.
• W2016090125 hasConcept C86554907 @default.
• W2016090125 hasConcept C86803240 @default.
• W2016090125 hasConcept C98274493 @default.
• W2016090125 hasConceptScore W2016090125C161624437 @default.
• W2016090125 hasConceptScore W2016090125C184235292 @default.
• W2016090125 hasConceptScore W2016090125C185592680 @default.
• W2016090125 hasConceptScore W2016090125C2777609662 @default.
• W2016090125 hasConceptScore W2016090125C502942594 @default.
• W2016090125 hasConceptScore W2016090125C55493867 @default.
• W2016090125 hasConceptScore W2016090125C62478195 @default.
• W2016090125 hasConceptScore W2016090125C86554907 @default.
• W2016090125 hasConceptScore W2016090125C86803240 @default.
• W2016090125 hasConceptScore W2016090125C98274493 @default.
• W2016090125 hasLocation W20160901251 @default.
• W2016090125 hasOpenAccess W2016090125 @default.
• W2016090125 hasPrimaryLocation W20160901251 @default.
• W2016090125 hasRelatedWork W1981588551 @default.
• W2016090125 hasRelatedWork W1984777958 @default.
• W2016090125 hasRelatedWork W2038141559 @default.
• W2016090125 hasRelatedWork W2056956513 @default.
• W2016090125 hasRelatedWork W2058825220 @default.
• W2016090125 hasRelatedWork W2079336580 @default.
• W2016090125 hasRelatedWork W2089728094 @default.
• W2016090125 hasRelatedWork W2093098485 @default.
• W2016090125 hasRelatedWork W2093809146 @default.
• W2016090125 hasRelatedWork W2261669934 @default.
• W2016090125 hasRelatedWork W2272173799 @default.
• W2016090125 hasRelatedWork W2335660484 @default.
• W2016090125 hasRelatedWork W2479610082 @default.
• W2016090125 hasRelatedWork W2539283095 @default.
• W2016090125 hasRelatedWork W2564736747 @default.
• W2016090125 hasRelatedWork W2605608630 @default.
• W2016090125 hasRelatedWork W2770755676 @default.
• W2016090125 hasRelatedWork W2980257051 @default.
• W2016090125 hasRelatedWork W2187781040 @default.
• W2016090125 hasRelatedWork W2475680381 @default.
• W2016090125 isParatext "false" @default.
• W2016090125 isRetracted "false" @default.
• W2016090125 magId "2016090125" @default.
• W2016090125 workType "article" @default.